Nicox (NICXF) Projected to Post Quarterly Earnings on Tuesday

Nicox (OTCMKTS:NICXF) is anticipated to issue its resultson Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.4660) per share and revenue of $3.8650 million for the quarter.

Nicox Stock Performance

Shares of OTCMKTS:NICXF remained flat at $0.30 during trading on Tuesday. The firm has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.30. Nicox has a 52 week low of $0.25 and a 52 week high of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.